Back to Search Start Over

Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial ( <scp>EDI‐PIO</scp> ) in chronic myeloid leukemia with deep molecular response

Tools

Authors Abstract Subjects Details